elmundo.es
🌐 85% Global Worthiness
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Progress
40% Bias Score
Good Health and Well-being